Controlled Substance Scheduling

The Controlled Substances Act of 1970 assigns a substance to one of five schedules according to abuse potential, accepted medical use and dependence liability. Schedule I means no accepted medical use and no lawful prescribing; schedules II through V carry descending restriction on prescribing, refills, recordkeeping and storage. Scheduling is normally done by DEA through an eight-factor analysis informed by a scientific and medical evaluation from HHS, and Congress can also schedule a substance directly.

Almost no therapeutic peptides are scheduled. Anabolic steroids were placed in schedule III by statute in 1990, with the definition widened in 2004 and again in 2014 to capture designer analogues, but growth hormone took a different route: it is not a controlled substance, yet section 303(e) of the Federal Food, Drug, and Cosmetic Act makes distribution of human growth hormone for uses other than approved indications a felony. Scheduling actions and analogue definitions do change, so a claim that a particular compound is unscheduled should be checked against the current DEA listing.

The distinction that matters is that unscheduled does not mean unregulated. A peptide with no schedule can simultaneously be an unapproved new drug, a misbranded article, an import violation and a doping offence. Scheduling governs diversion control and criminal exposure; the food and drug provisions govern whether the substance may be sold as a medicine at all.

The argument you will meet is that because a peptide appears on no schedule, selling it must be lawful. It is a category error, and it explains why enforcement against grey-market peptide sellers usually arrives as a warning letter or an import alert rather than as a DEA action. State law adds another layer, since some states schedule substances the federal list does not.